VNS Treatment for Fatigue

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mayo Clinic in Rochester, Rochester, MN
Fatigue+3 More
vagal nerve stimulator - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to evaluate the impact of vagal nerve stimulation on patients with post COVID syndrome who have fatigue and headache.

Eligible Conditions

  • Fatigue
  • Post COVID Syndrome
  • Headache

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Baseline to 12 weeks

Baseline to 12 weeks
Change in Post-COVID Functional Status Score

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Non-VNS Treatment
1 of 2
VNS Treatment
1 of 2
Active Control
Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: VNS Treatment · No Placebo Group · N/A

VNS Treatment
Device
Experimental Group · 1 Intervention: vagal nerve stimulator · Intervention Types: Device
Non-VNS TreatmentNoIntervention Group · 1 Intervention: Non-VNS Treatment · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 12 weeks

Trial Background

Ravindra Ganesh, Principal Investigator
Principal Investigator
Mayo Clinic
Closest Location: Mayo Clinic in Rochester · Rochester, MN
Photo of Rochester  1Photo of Rochester  2Photo of Rochester  3
2021First Recorded Clinical Trial
6 TrialsResearching Fatigue
502 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a headache.\n
You have the ability to participate in all aspects of the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.